company background image
LHDX

Lucira HealthNasdaqGS:LHDX Stock Report

Market Cap

US$226.0m

7D

1.9%

1Y

n/a

Updated

20 Oct, 2021

Data

Company Financials +
LHDX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LHDX Overview

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits.

Lucira Health Competitors

Danaher

NYSE:DHR

US$224.7b

Abbott Laboratories

NYSE:ABT

US$218.6b

Becton Dickinson

NYSE:BDX

US$70.9b

Cue Health

NasdaqGS:HLTH

US$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for Lucira Health
Historical stock prices
Current Share PriceUS$5.84
52 Week HighUS$4.23
52 Week LowUS$37.99
Beta0
1 Month Change-23.96%
3 Month Change-18.55%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-76.62%

Recent News & Updates

Jun 29
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?

Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

LHDXUS Medical EquipmentUS Market
7D1.9%2.4%4.0%
1Yn/a22.7%30.5%

Return vs Industry: Insufficient data to determine how LHDX performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how LHDX performed against the US Market.

Price Volatility

Is LHDX's price volatile compared to industry and market?
LHDX volatility
LHDX Beta0
Industry Beta0.88
Market Beta1

Stable Share Price: LHDX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: LHDX's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201384Erik Engelsonhttps://www.lucirahealth.com

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

Lucira Health Fundamentals Summary

How do Lucira Health's earnings and revenue compare to its market cap?
LHDX fundamental statistics
Market CapUS$226.00m
Earnings (TTM)-US$58.51m
Revenue (TTM)US$17.22m

13.1x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LHDX income statement (TTM)
RevenueUS$17.22m
Cost of RevenueUS$19.81m
Gross Profit-US$2.59m
ExpensesUS$55.92m
Earnings-US$58.51m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.51
Gross Margin-15.04%
Net Profit Margin-339.72%
Debt/Equity Ratio0%

How did LHDX perform over the long term?

See historical performance and comparison

Valuation

Is Lucira Health undervalued compared to its fair value and its price relative to the market?

1.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LHDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LHDX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LHDX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: LHDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LHDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LHDX is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (4.4x).


Future Growth

How is Lucira Health forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-1.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LHDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LHDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LHDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LHDX's revenue (62.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: LHDX's revenue (62.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LHDX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Lucira Health performed over the past 5 years?

-232.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: LHDX is currently unprofitable.

Growing Profit Margin: LHDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LHDX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LHDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LHDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).


Return on Equity

High ROE: LHDX has a negative Return on Equity (-27.11%), as it is currently unprofitable.


Financial Health

How is Lucira Health's financial position?


Financial Position Analysis

Short Term Liabilities: LHDX's short term assets ($215.9M) exceed its short term liabilities ($28.6M).

Long Term Liabilities: LHDX's short term assets ($215.9M) exceed its long term liabilities ($254.0K).


Debt to Equity History and Analysis

Debt Level: LHDX is debt free.

Reducing Debt: LHDX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LHDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LHDX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 80.2% each year.


Dividend

What is Lucira Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LHDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LHDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LHDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LHDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LHDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Erik Engelson (61 yo)

2.67yrs

Tenure

US$775,017

Compensation

Mr. Erik T. Engelson has been the President and Chief Executive Officer of Lucira Health, Inc. since February 8, 2019 and has been its Director since March 2019. Mr. Engelson served as Chief Executive Offi...


CEO Compensation Analysis

Compensation vs Market: Erik's total compensation ($USD775.02K) is about average for companies of similar size in the US market ($USD1.07M).

Compensation vs Earnings: Insufficient data to compare Erik's compensation with company performance.


Leadership Team

Experienced Management: LHDX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: LHDX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: LHDX only recently listed within the past 12 months.


Top Shareholders

Company Information

Lucira Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lucira Health, Inc.
  • Ticker: LHDX
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$226.001m
  • Shares outstanding: 38.70m
  • Website: https://www.lucirahealth.com

Number of Employees


Location

  • Lucira Health, Inc.
  • 1412 62nd Street
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 23:27
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.